Acute monocytic leukemia: Difference between revisions

Jump to navigation Jump to search
m (Robot: Changing Category:Disease state to Category:Disease)
(Redirected page to Acute myeloid leukemia)
 
(5 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{Infobox_Disease |
#REDIRECT [[Acute myeloid leukemia]]
  Name          = Acute monocytic leukemia |
  Image          = |
  Caption        = |
  DiseasesDB    = |
  ICD10          = {{ICD10|C|93|0|c|81}} |
  ICD9          = {{ICD9|206.0}} |
  ICDO          = |
  OMIM          = |
  MedlinePlus    = |
  MeshID        = D007948 |
}}
{{Search infobox}}
{{CMG}}
 
{{Editor Help}}
 
==Overview==
'''Acute monocytic leukemia''' ('''AMoL''', or '''AML-M5''') is considered a type of [[acute myeloid leukemia]]. In order to fulfill [[World Health Organization]] (WHO) criteria for AML-5, a patient must have greater than 20% blasts in the bone marrow, and of these, greater than 80% must be of the monocytic lineage. A further subclassification (M5a versus M5b) is made depending on whether the monocytic cells are predominantly monoblasts (>80%) ('''acute monoblastic leukemia''') or a mixture of monoblasts and promonocytes (<80% blasts). Monoblasts can be distinguished by having a roughly circular nucleus, delicate lacy chromatin, and abundant, often basophilic cytoplasm. These cells may also have pseudopods. By contrast, promonocytes have a more convoluted nucleus, and their cytoplasm may contain metachromatic granules. Monoblasts are typically MPO negative and promonocytes are MPO variable. Both monoblasts and promonocytes stain positive for non-specific esterase (NSE), however NSE may often be negative.
 
Immunophenotypically, M5-AML variably express myeloid ([[CD13]], [[CD33]]) and monocytic ([[CD11b]], [[CD11c]]) markers. Cells may aberrantly express B cels marker [[CD20]] and the NK marker [[CD56]]. Monoblasts may be positive for [[CD34]].
 
M5 is associated with characteristic chromosomal abnormalities, often involving 11q23 or t(9;11)affecting the MLL locus, however the MLL translocation is also found in other AML subtypes. MLL is believed to be prognostically unfavorable in AML-M5 compared to other genetic alterations involving MLL such as t(9;11) The t(8;16) translocation in MLL is associated with hemophagocytosis.
 
AML-M5 is thought to be associated with exposure to epidophyllotoxins.
 
AML-M5 is treated with intensive chemotherapy (such as anthracyclines) or with bone marrow transplantation.
==External links==
* [http://pathy.med.nagoya-u.ac.jp/atlas/doc/node47.html AML images at Nagoya]
* [http://www.hmds.org.uk/insets/m5.htm AML Images]
 
{{Hematology}}
{{Hematological malignancy histology}}
{{SIB}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
 
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Types of cancer]]
[[Category:Oncology]]

Latest revision as of 20:01, 5 May 2016